Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC with Neoadjuvant Chemoradiation in Rectal Cancer
NCT03300544Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Mar 2022
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in rectal adenocarcinoma, sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicities and Maximum Tolerated Dose. Started May 2019; status: terminated.
02
Drugs
talimogene laherparepvec
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT03300544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300544.